Second-Line Treatment with Axitinib Plus Toripalimab in Metastatic Renal Cell Carcinoma: A Retrospective Multicenter Study | Zendy

Jiwei Huang | Zendy; Guohai Shi | Zendy; Yueming Wang | Zendy; Ping Wang | Zendy; Jin Zhang | Zendy; Wen Kong | Zendy; Yong Huang | Zendy; Shuo Wang | Zendy; Wei Xue | Zendy

Open Access

Second-Line Treatment with Axitinib Plus Toripalimab in Metastatic Renal Cell Carcinoma: A Retrospective Multicenter Study

Author(s) -

Jiwei Huang,

Guohai Shi,

Yueming Wang,

Ping Wang,

Jin Zhang,

Wen Kong,

Yong Huang,

Shuo Wang,

Wei Xue

Publication year - 2022

Publication title -

future oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.857

H-Index - 72

eISSN - 1744-8301

pISSN - 1479-6694

DOI - 10.2217/fon-2021-1267

Subject(s) - medicine , axitinib , renal cell carcinoma , oncology , second line , multicenter study , retrospective cohort study , first line , sunitinib , randomized controlled trial

Aim: To evaluate the efficacy and safety of second-line treatment with axitinib plus toripalimab in patients with metastatic renal cell carcinoma and failure of VEGFR tyrosine kinase inhibitors. Methods: Data were collected restropectively. Kaplan–Meier analysis and Cox proportional hazards model determined the efficacy outcomes. Results: In 57 patients, objective response rate was 31.6% and median progression-free survival (PFS) was 11.7 months, while median overall survival was not reached. Median PFS was not reached in favorable-risk patients, whereas PFS of 11.0 and 7.8 months were observed in intermediate- and poor-risk patients, respectively (p = 0.011). The treatment-related toxicities were mild in nature. Conclusion: Second-line therapy with axitinib plus toripalimab provided durable response rate, longer PFS and a tolerable safety profile.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research